- HLA-G, a target of IMB-201, is expressed in only tumor tissues, not normal tissues except placenta of pregnant female, indicating that it is a kind of tumor specific antigen (TSA).
- HLA-G, expressed in tumor tissues, leads immune evasiveness of tumor by suppressing activity of cytotoxic T cell, NK cell, Macrophage, and B cell in tumor microenvironment (TME) as well as enhancing differentiation of Treg.
- IMB-201, a specific antibody against HLA-G, normalizes TME by blocking interaction of inhibitory receptors, a reason for immune evasiveness of tumor, resulting killing of tumor cells. Furthermore, it has been designed to have a dual mechanism of action by additional tumor killing effect through Fc effector function based on tumor specific expression of HLA-G (TSA).

- We have developed antibody having a superior efficacy in just a form of monoclonal antibody compared to competitor by specifically binding to HLA-G as well as efficiently blocking interaction with inhibitory receptors via our revolutionary platform, IMBolution.

- Using a strength of the IMB-201, broad safety margin due to targeting TSA, HLA-G, we are trying to develop revolutionary new drug having an enhanced therapeutic index by grafting technology to improve efficacy of IMB-201 antibody to satisfy medical unmet needs of the established immune check-point inhibitors.